Patents by Inventor James H. Morrissey
James H. Morrissey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20100297257Abstract: A method for treating a coagulation deficient patient comprises administering an amount of polyP to the patient sufficient to reduce the PT Test value or Dilute PT Test value of the plasma of the patient.Type: ApplicationFiled: November 3, 2008Publication date: November 25, 2010Applicant: National Institutes of Health (NIH), U.S. Dept. of Health and Human Services (DHHS)Inventors: Stephanie A. Smith, James H. Morrissey
-
Publication number: 20100284998Abstract: A fibrin sealant, comprises (a) thrombin, (b) fibrinogen, (c) polyP, and (d) calcium. The thrombin and the fibrinogen are separated prior to application.Type: ApplicationFiled: October 2, 2008Publication date: November 11, 2010Applicant: BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOISInventors: Stephanie A. Smith, James H. Morrissey
-
Publication number: 20100143492Abstract: A thromboplastin reagent comprises (i) TF, (ii) a phospholipid, and (iii) a polyP TFPI blocker.Type: ApplicationFiled: October 20, 2009Publication date: June 10, 2010Inventors: JAMES H. MORRISSEY, STEPHANIE A. SMITH, ROBERTO DOCAMPO, NICOLA J. MUTCH
-
Patent number: 7682808Abstract: A thromboplastin reagent comprises (i) TF, (ii) a phospholipid, and (iii) a polyP TFPI blocker.Type: GrantFiled: February 23, 2006Date of Patent: March 23, 2010Assignee: The Board of Trustees of the University of IllinoisInventors: James H. Morrissey, Stephanie A. Smith, Roberto Docampo, Nicola J. Mutch
-
Patent number: 7622437Abstract: Tissue Factor (natural or recombinant truncated) can be incorporated into stable, soluble nanoscale particles so that activity is maintained. These particles can be used as a reagent in prothrombin clotting time assays or they can be used in therapeutic compositions for use in humans or animals. Therapeutic settings can include supplementation in the case of a genetic deficiency, uncontrolled bleeding, surgical incisions or seepage, thrombocytopenia, soft tissue trauma or other trauma, to effect tumor regression or to inhibit tumor growth.Type: GrantFiled: October 27, 2005Date of Patent: November 24, 2009Assignee: The Board of Trustees of the University of IllinoisInventors: James H. Morrissey, Vincent S. Pureza, Stephen G. Sligar
-
Publication number: 20090176246Abstract: A method for determining the concentration of factor VIIa-antithrombin complexes is disclosed which has application to estimating the level of intravascular exposure of tissue factor, assessing patient risk for hypercoagulation or other coagulopathies, and monitoring patients for factor VIIa-antithrombin complexes over time which can reveal changes in risk for hypercoagulation or other coagulopathies and/or effectiveness of anticoagulant therapy. Antibodies suitable for use in an in vitro assay for determining the concentration of factor VIIa-antithrombin complexes and methods for making the same are also disclosed.Type: ApplicationFiled: December 18, 2008Publication date: July 9, 2009Applicant: OKLAHOMA MEDICAL RESEARCH FOUNDATIONInventor: James H. Morrissey
-
Patent number: 7494782Abstract: A method for determining the concentration of factor VIIa-antithrombin complexes is disclosed which has application to estimating the level of intravascular exposure of tissue factor, assessing patient risk for hypercoagulation or other coagulopathies, and monitoring patients for factor VIIa-antithrombin complexes over time which can reveal changes in risk for hypercoagulation or other coagulopathies and/or effectiveness of anticoagulant therapy. Antibodies suitable for use in an in vitro assay for determining the concentration of factor VIIa-antithrombin complexes and methods for making the same are also disclosed.Type: GrantFiled: July 2, 2002Date of Patent: February 24, 2009Inventor: James H. Morrissey
-
Publication number: 20090047356Abstract: Tissue Factor (natural or recombinant truncated) can be incorporated into stable, soluble nanoscale particles so that activity is maintained. These particles can be used as a reagent in prothrombin clotting time assays or they can be used in therapeutic compositions for use in humans or animals. Therapeutic settings can include supplementation in the case of a genetic deficiency, uncontrolled bleeding, surgical incisions or seepage, thrombocytopenia, soft tissue trauma or other trauma, to effect tumor regression or to inhibit tumor growth.Type: ApplicationFiled: September 16, 2008Publication date: February 19, 2009Applicant: The Board of Trustees of the University of IllinoisInventors: James H. Morrissey, Vincent S. Pureza, Stephen G. Sligar
-
Publication number: 20080260858Abstract: A thromboplastin reagent comprises: (i) activated sTF, (ii) a metal-chelating lipid, (iii) a metal ion, and (iv) a phospholipid. Activated sTF preferably includes the extracellular domain of TF and an oligohistidine moiety having at least 2 histidine residues, more preferably 2-10 histidine residues. Preferably, the histidine residues are consecutive. Attaching a metal binding domain, such as an oligohistidine tag, to the C-terminus of sTF allows the protein to bind to phospholipid vesicles that contain metal-chelating lipid. Metal complexes of this activated sTF and metal-chelating lipids have all of the desirable expression, handling, and solubility characteristics of sTF, and exhibit procoagulant activities in plasma clotting tests that are comparable to relipidated rTF. In addition, it was discovered that, under some circumstances, Ni-lipids are themselves procoagulant, even in the absence of activated sTF.Type: ApplicationFiled: February 10, 2006Publication date: October 23, 2008Applicant: The Board of Trustees of the University of IllnoisInventors: James H. Morrissey, Emily Kerestes Waters
-
Patent number: 7148067Abstract: A thromboplastin reagent includes tissue factor, Factor VIIa, and a net negatively charged phospholipid. The thromboplastin reagent is a synthetic thromboplastin reagent, and is in dried form.Type: GrantFiled: August 31, 2004Date of Patent: December 12, 2006Assignee: The Board of Trustees of the University of IllinoisInventors: James H. Morrissey, Stephanie A. Smith
-
Publication number: 20040197842Abstract: A method for determining the concentration of factor VIIa-antithrombin complexes is disclosed which has application to estimating the level of intravascular exposure of tissue factor, assessing patient risk for hypercoagulation or other coagulopathies, and monitoring patients for factor VIIa-antithrombin complexes over time which can reveal changes in risk for hypercoagulation or other coagulopathies and/or effectiveness of anticoagulant therapy. Antibodies suitable for use in an in vitro assay for determining the concentration of factor VIIa-antithrombin complexes and methods for making the same are also disclosed.Type: ApplicationFiled: February 27, 2004Publication date: October 7, 2004Inventor: James H. Morrissey
-
Patent number: 6303596Abstract: The invention relates to selective induction of cell death by apoptosis and applicability to treatment of leukemias.Type: GrantFiled: March 1, 2000Date of Patent: October 16, 2001Assignee: Oklahoma Medical Research FoundationInventors: James H. Morrissey, Anne Hamik
-
Patent number: 6001978Abstract: DNA segments that include DNA sequences defining a structural gene coding for a human tissue factor heavy chain protein and a precursor form of that protein are disclosed. Recombinant DNA molecules capable of expressing a human tissue factor heavy chain protein are also disclosed. Further disclosed are human tissue factor heavy chain binding site polypeptide analogs as well as methods for their use.Type: GrantFiled: April 22, 1997Date of Patent: December 14, 1999Assignee: The Scripps Research InstituteInventors: Thomas S. Edgington, James H. Morrissey
-
Patent number: 5750358Abstract: An assay for activated factor VII (factor VIIa) has been developed using truncated tissue factor (tTF), a soluble mutant form of tissue factor (TF) that retains the cofactor function of TF toward factor VIIa. Unlike full-length TF, however, tTF appears not to support the conversion of factor VII to VIIa. As a result, the tTF assay for factor VIIa is free from interference from factor VII in the plasma and is therefore specific for factor VIIa. The assay is much simpler than existing assays, because it is a single-stage clotting assay performed almost identically to a prothrombin time (PT) assay. It is also considerably more sensitive than current assays for factor VIIa in plasma. Since the tTF assay is calibrated against a factor VIIa standard, it yields an absolute concentration of factor VIIa in ng/ml.Type: GrantFiled: June 5, 1995Date of Patent: May 12, 1998Assignee: Oklahoma Medical Research FoundationInventor: James H. Morrissey
-
Patent number: 5741658Abstract: An kit for an assay for measuring activated factor VII (factor VIIa) is disclosed which employs a reagent comprising truncated tissue factor (tTF), a soluble mutant form of tissue factor (TF) that retains the cofactor function of TF toward factor VIIa, but does not support the conversion of factor VII to VIIa. As a result, the tTF assay for factor VIIa is free from interference from factor VII in the plasma and is therefore specific for factor VIIa. The assay is much simpler than existing assays, because it is a single-stage clotting assay performed almost identically to a prothrombin time (PT) assay. It is also considerably more sensitive than current assays for factor VIIa in plasma. Since the tTF assay is calibrated against a factor VIIa standard, it yields an absolute concentration of factor VIIa in ng/ml.Type: GrantFiled: June 5, 1995Date of Patent: April 21, 1998Assignee: Oklahoma Medical Research FoundationInventor: James H. Morrissey
-
Patent number: 5622931Abstract: DNA segments that include DNA sequences defining a structural gene coding for a human tissue factor heavy chain protein and a precursor form of that protein are disclosed. Recombinant DNA molecules capable of expressing a human tissue factor heavy chain protein are also disclosed. Further disclosed are human tissue factor heavy chain binding site polypeptide analogs as well as methods for their use.Type: GrantFiled: April 29, 1992Date of Patent: April 22, 1997Assignee: The Scripps Research InstituteInventors: Thomas S. Edgington, James H. Morrissey
-
Patent number: 5504067Abstract: It has been discovered that it is possible to administer truncated tissue factor, not having the transmembrane region (tTF) in combination with factor VIIa (FVIIa) to treat bleeding disorders such as those resulting from hemophilia or cirrhosis of the liver. Preferably, the tTF is administered to produce up to 10 .mu.g tTF/ml of plasma. The FVIIa is administered to produce levels of between 40 ng FVIIa/ml and 4 .mu.g FVIIa/ml of plasma. The effective dosages of both tTF and FVIIa are significantly and surprisingly less than the administration of either alone to stop bleeding. Examples demonstrate safety and efficacy in normal and hemophilic dogs.Type: GrantFiled: October 12, 1994Date of Patent: April 2, 1996Assignee: Oklahoma Medical Research FoundationInventors: James H. Morrissey, Philip C. Comp
-
Patent number: 5504064Abstract: It has been discovered that it is possible to administer truncated tissue factor (not having the transmembrane region) (tTF) in combination with factor VIIa (FVIIa) or an activator of endogenous factor VII to treat bleeding disorders such as those resulting from hemophilia or cirrhosis of the liver. The tTF is administered to produce up to 10 .mu.g tTF/ml of plasma. The FVIIa or FVII activator is administered to produce levels of between 40 ng FVIIa/ml and 700 ng FVIIa/ml of plasma. The effective dosages of both tTF and FVIIa/factor VII activator are significantly and surprisingly less than the administration of either alone to stop bleeding. Examples demonstrate safety and efficacy in normal and hemophilic dogs.Type: GrantFiled: February 19, 1993Date of Patent: April 2, 1996Assignee: Oklahoma Medical Research FoundationInventors: James H. Morrissey, Philip C. Comp
-
Patent number: 5472850Abstract: An assay for activated factor VII (factor VIIa) has been developed using truncated tissue factor (tTF), a soluble mutant form of (tTF) that retains the cofactor function of TF toward factor VIIa. Unlike full-length TF, however, tTF appears not to support the conversion of factor VII to VIIa. As a result, the tTF assay for factor VIIa is free from interference from factor VII in the plasma and is therefore specific for factor VIIa. The assay is much simpler than existing assays, because it is a single-stage clotting assay performed almost identically to a prothrombin time assay. It is also considerably more sensitive than current assays for factor VIIa in plasma. Since the tTF assay is calibrated against a factor VIIa standard, it yields an absolute concentration of factor VIIa in ng/ml.Type: GrantFiled: April 10, 1991Date of Patent: December 5, 1995Assignee: Oklahoma Medical Research FoundationInventor: James H. Morrissey
-
Patent number: 5374617Abstract: It has been discovered that it is possible to administer truncated tissue factor (not having the transmembrane region) (tTF) in combination with factor VIIa (F VIIa) to treat bleeding disorders such as those resulting from hemophilia or cirrhosis of the liver. The tTF is administered to produce up to 10 .mu.g tTF/ml of plasma. The F VIIa is administered to produce levels of between 40 ng VIIa/ml and 4 .mu.g F VIIa/ml of plasma. The effective dosages of both tTF and VIIa are significantly and surprisingly less than the administration of either alone to stop bleeding. Examples demonstrate safety and efficacy in normal and hemophilic dogs.Type: GrantFiled: May 13, 1992Date of Patent: December 20, 1994Assignee: Oklahoma Medical Research FoundationInventors: James H. Morrissey, Philip C. Comp